1. Home
  2. DIBS vs AGEN Comparison

DIBS vs AGEN Comparison

Compare DIBS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 1stdibs.com Inc.

DIBS

1stdibs.com Inc.

HOLD

Current Price

$5.53

Market Cap

194.7M

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.93

Market Cap

178.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DIBS
AGEN
Founded
2000
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
194.7M
178.2M
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
DIBS
AGEN
Price
$5.53
$3.93
Analyst Decision
Buy
Buy
Analyst Count
1
2
Target Price
$7.00
$14.50
AVG Volume (30 Days)
133.9K
1.1M
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
22.45
100.00
EPS
N/A
N/A
Revenue
$89,620,000.00
$42,877,086.00
Revenue This Year
$3.12
$107.63
Revenue Next Year
$1.72
N/A
P/E Ratio
N/A
$8.89
Revenue Growth
1.54
89.95
52 Week Low
$2.35
$2.63
52 Week High
$6.62
$7.34

Technical Indicators

Market Signals
Indicator
DIBS
AGEN
Relative Strength Index (RSI) 44.54 49.63
Support Level $5.27 $3.92
Resistance Level $5.63 $4.58
Average True Range (ATR) 0.23 0.40
MACD -0.01 -0.08
Stochastic Oscillator 13.58 22.67

Price Performance

Historical Comparison
DIBS
AGEN

About DIBS 1stdibs.com Inc.

1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: